股本结构
单位：万股
| 公告日期 | 2026-08-11 | 2026-08-11 | 2026-05-07 | 2026-04-30 | 2026-04-30 | 2026-05-07 |
|---|---|---|---|---|---|---|
| 证券总股本 | 326.49 | 294.56 | 270.28 | 264.96 | 260.70 | 254.05 |
| 普通股本 | 326.49 | 294.56 | 270.28 | 264.96 | 260.70 | 254.05 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-08-07 | 2026-06-30 | 2026-05-06 | 2026-04-23 | 2026-04-15 | 2026-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-11 | 326.49 | 未披露 | 定期报告 | 2026-08-07 |
| 2026-08-11 | 294.56 | 未披露 |
更多>>
From March 31,2026 to June 30,2026
Issuance of common stock in ATM offering, net of $60 issuance costs
Issuance of common stock in employee stock purchase plan
Issuance of common stock to CEO in lieu of cash bonus
|
2026-06-30 |
| 2026-05-07 | 270.28 | 未披露 | 定期报告 | 2026-05-06 |
| 2026-04-30 | 264.96 | 未披露 | 定期报告 | 2026-04-23 |
| 2026-04-30 | 260.70 | 未披露 | 定期报告 | 2026-04-15 |
| 2026-05-07 | 254.05 | 未披露 |
更多>>
From December 31,2025 to March 31, 2026
Issuance of common stock in ATM offering, net of $7 issuance costs
Reverse stock split adjustment
|
2026-03-31 |
| 2026-03-27 | 254.05 | 未披露 | 定期报告 | 2026-03-26 |
| 2026-02-13 | 253.39 | 未披露 |
更多>>
a 1-for-25 reverse stock split of the Company's common stock
|
2026-02-19 |
| 2026-02-13 | 6334.66 | 未披露 | 定期报告 | 2026-02-12 |
| 2025-11-06 | 6006.50 | 未披露 | 定期报告 | 2025-11-05 |
| 2025-11-03 | 5999.90 | 未披露 |
更多>>
Common Stock offered 5,000,000 shares by the company
|
2025-11-03 |
| 2025-11-03 | 5499.90 | 未披露 | 定期报告 | 2025-10-30 |
| 2025-11-06 | 4906.86 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of common stock in ATM offering, net of $301 issuance costs
|
2025-09-30 |
| 2025-09-09 | 4905.55 | 未披露 | 定期报告 | 2025-08-29 |
| 2025-08-07 | 4705.77 | 未披露 | 定期报告 | 2025-08-06 |
| 2025-08-04 | 4603.51 | 未披露 | 定期报告 | 2025-07-31 |
| 2025-08-07 | 2616.64 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock in public offerings, net of $698 issuance costs
Issuance of common stock in employee stock purchase plan
|
2025-06-30 |
| 2025-06-12 | 2507.32 | 未披露 |
更多>>
Common stock offered 6,675,000 shares by the company
|
2025-06-13 |
| 2025-04-25 | 1839.82 | 未披露 |
更多>>
Common stock offered 3,133,333 shares by the company
|
2025-04-28 |
| 2025-05-13 | 1526.49 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock in ATM offering, net of $17 issuance costs
|
2025-03-31 |
| 2025-03-13 | 1518.09 | 未披露 | 定期报告 | 2025-03-01 |
| 2025-03-13 | 1512.29 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock in registered direct offering, net of $321 issuance costs
Issuance of common stock in ATM offering, net of $82 issuance costs
Issuance of common stock in exchange for services
Exercise of options
Exercise of warrants
|
2024-12-31 |
| 2024-11-22 | 1510.48 | 未披露 |
更多>>
Common Stock offered 1,237,113 shares by the company
|
2024-11-22 |
| 2024-11-13 | 1386.77 | 未披露 | 定期报告 | 2024-11-12 |
| 2024-11-13 | 1386.39 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Exercise of options
Issuance of common stock in exchange for services
Issuance of common stock in ATM offering, net of $82 issuance costs
|
2024-09-30 |
| 2024-08-08 | 1377.19 | 未披露 | 定期报告 | 2024-08-07 |
| 2024-08-08 | 1371.29 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Exercise of options
|
2024-06-30 |
| 2024-05-09 | 1371.19 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Exercise of warrants
|
2024-03-31 |
| 2023-11-13 | 1370.94 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Exercise of options and warrants
Issuance of common stock in connection with overallotment, net of $371,583 issuance costs
|
2023-09-30 |
| 2023-07-10 | 1368.44 | 未披露 |
更多>>
On July 10, 2023, Intensity Therapeutics, Inc. (the “Company”) announced that in connection with its upsized initial public offering of 3,900,000 shares of its common stock, par value $0.0001 per share (“Common Stock”), as previously reported in a Current Report on Form 8-K filed on July 5, 2023, The Benchmark Company, LLC, as representative of the underwriters (the “Representative”), has exercised in full its option to purchase 585,000 additional shares of Common Stock at a public offering price of $5.00 per share for additional gross proceeds of $2,925,000.
|
2023-07-10 |
| 2023-08-14 | 1309.94 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock in public offering for cash, net of $3,031,484 issuance costs
Issuance of preferred stock for anti-dilution clauses
Conversion of convertible notes into common stock
Conversion of preferred stock into common stock
|
2023-06-30 |
From March 31,2026 to June 30,2026
Issuance of common stock in ATM offering, net of $60 issuance costs
Issuance of common stock in employee stock purchase plan
Issuance of common stock to CEO in lieu of cash bonus
From December 31,2025 to March 31, 2026
Issuance of common stock in ATM offering, net of $7 issuance costs
Reverse stock split adjustment
a 1-for-25 reverse stock split of the Company's common stock
Common Stock offered 5,000,000 shares by the company
From June 30, 2025 to September 30, 2025
Issuance of common stock in ATM offering, net of $301 issuance costs
From March 31, 2025 to June 30, 2025
Issuance of common stock in public offerings, net of $698 issuance costs
Issuance of common stock in employee stock purchase plan
Common stock offered 6,675,000 shares by the company
Common stock offered 3,133,333 shares by the company
From December 31, 2024 to March 31, 2025
Issuance of common stock in ATM offering, net of $17 issuance costs
From December 31, 2023 to December 31, 2024
Issuance of common stock in registered direct offering, net of $321 issuance costs
Issuance of common stock in ATM offering, net of $82 issuance costs
Issuance of common stock in exchange for services
Exercise of options
Exercise of warrants
Common Stock offered 1,237,113 shares by the company
From June 30, 2024 to September 30, 2024
Exercise of options
Issuance of common stock in exchange for services
Issuance of common stock in ATM offering, net of $82 issuance costs
From March 31, 2024 to June 30, 2024
Exercise of options
From December 31, 2023 to March 31, 2024
Exercise of warrants
From June 30, 2023 to September 30, 2023
Exercise of options and warrants
Issuance of common stock in connection with overallotment, net of $371,583 issuance costs
On July 10, 2023, Intensity Therapeutics, Inc. (the “Company”) announced that in connection with its upsized initial public offering of 3,900,000 shares of its common stock, par value $0.0001 per share (“Common Stock”), as previously reported in a Current Report on Form 8-K filed on July 5, 2023, The Benchmark Company, LLC, as representative of the underwriters (the “Representative”), has exercised in full its option to purchase 585,000 additional shares of Common Stock at a public offering price of $5.00 per share for additional gross proceeds of $2,925,000.
From March 31, 2023 to June 30, 2023
Issuance of common stock in public offering for cash, net of $3,031,484 issuance costs
Issuance of preferred stock for anti-dilution clauses
Conversion of convertible notes into common stock
Conversion of preferred stock into common stock